건선성 관절염 치료 시장 규모, 점유율, 동향 분석 보고서 : 약제 클래스별, 유형별, 투여 경로별, 지역별, 부문별 예측(2025-2030년)

Psoriatic Arthritis Treatment Market Size, Share & Trends Analysis Report By Drug Class (NSAIDs, DMARDs, Biologics), By Type (Prescriptions, OTC), By Route Of Administration (Topical, Oral, Injectable), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,323,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,722,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,520,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

건선성 관절염 치료 시장 개요

건선성 관절염 치료제 세계 시장 규모는 2024년에 113억 5,000만 달러로 추정되며, 2025년부터 2030년까지 연평균 9.8% 성장하여 2030년에는 199억 1,000만 달러에 달할 것으로 예측됩니다. 신제품 출시, 유망한 파이프라인, 소비자 인식의 대폭 상승, 질병 부담 증가 등이 시장 성장을 가속하는 요인으로 기대되고 있습니다.

건선성 관절염은 건선에 동반되는 만성 퇴행성 질환입니다. 적절하고 적시에 치료하지 않으면 이 질환은 돌이킬 수 없는 관절 장애를 유발할 수 있습니다. 정확한 원인 요인은 아직 밝혀지지 않았지만, 연구에 따르면 약 40%가 유전적 요인에 기인하는 것으로 추정되고 있습니다.

건선성 관절염은 류마티스 관절염이나 통풍으로 오진되는 경우가 있습니다. 그러나 민간 및 공공 기관에서 진행하는 여러 캠페인의 도움을 받아 소비자의 인식이 높아진다면 오진이나 잘못된 치료의 비율은 줄어들 것으로 보입니다. 또한, 치료비 상승과 일부 약물의 부작용이 시장 성장을 억제할 것으로 예측됩니다.

생물학적 제제의 표적 작용과 바이오시밀러의 등장으로 관절염 건선 치료에 큰 패러다임의 변화가 일어나고 있습니다. 그러나 안전성과 유효성이 개선된 가성비 높은 의약품에 대한 소비자 수요는 시장 역학에 긍정적인 영향을 미칠 것으로 보입니다.

신흥 시장의 의료 인프라 개선과 보험 적용 확대도 매우 중요합니다. 아시아태평양 및 라틴아메리카 국가에서는 의료 시스템이 빠르게 개선되고 있으며, 고가의 생물학적 제제에 대한 접근성이 확대되고 있습니다. 이러한 시장이 성숙해짐에 따라, 다국적 제약사와 국내 제약사 모두에게 지금까지 충분히 서비스를 받지 못했던 사람들을 끌어들일 수 있는 새로운 기회를 제공하게 될 것입니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 건선성 관절염 치료 시장 변수, 동향, 범위

• 시장 계통 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 건선성 관절염 치료 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석

제4장 건선성 관절염 치료 시장 : 약제 클래스 추정·동향 분석

• 약물 클래스 부문 대시보드
• 건선성 관절염 치료 시장 : 약제 클래스 변동 분석
• 세계의 건선성 관절염 치료 시장 규모와 동향 분석(약제 클래스별, 2018-2030년)
• NSAIDs
• DMARD
• 생물학적 제제
• 기타

제5장 건선성 관절염 치료 시장 : 유형 추정·동향 분석

• 유형 부문 대시보드
• 건선성 관절염 치료 시장 : 유형 변동 분석
• 건선성 관절염 치료 세계 시장 규모와 동향 분석(유형별, 2018-2030년)
• 처방전
• 시판약

제6장 건선성 관절염 치료 시장 : 투여 경로 추정·동향 분석

• 투여 경로 부문 대시보드
• 건선성 관절염 치료 시장 : 투여 경로 변동 분석
• 세계의 건선성 관절염 치료 시장 규모와 동향 분석(투여 경로별, 2018-2030년)
• 외용
• 경구
• 주사제

제7장 건선성 관절염 치료 시장 : 지역 추정·동향 분석

• 지역 시장 대시보드
• 지역별 시장 점유율 분석, 2024년 및 2030년
• 지역별 연속 바이오프로세스 시장 : 주요 포인트
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제8장 경쟁 구도

• 주요 시장 진출기업의 최근 동향과 영향 분석
• 기업/경쟁 분류
• 벤더 구도
  • Key company heat map analysis, 2024
• 기업 개요
  • AbbVie Inc.
  • Amgen Inc.
  • Johnson &Johnson Services, Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Pfizer, Inc.
  • UCB SA

LSH

영문 목차

영문목차

Psoriatic Arthritis Treatment Market Summary

The global psoriatic arthritis market size was estimated at USD 11.35 billion in 2024 and is projected toprojected to reach USD 19.91 billion by 2030, growing at a CAGR of 9.8% from 2025 to 2030. The new product launches, promising pipeline, a significant rise in consumer awareness, and increasing disease burden are some factors expected to fuel market growth.

Psoriatic arthritis is a chronic degenerative condition associated with psoriasis. In the absence of proper and timely treatment, the disease may lead to irreversible joint damage. Although the exact causative factors remain unknown, research suggests that nearly 40% of cases are attributable to genetic factors.

Psoriatic arthritis may be misdiagnosed as rheumatoid arthritis or gout. However, heightened consumer awareness, aided by multiple campaigns organized by private and public organizations, is likely to reduce the rates of misdiagnosis or incorrect treatment. In addition, the high cost of treatment and the adverse effects of some drugs are expected to restrain market growth.

There is a significant paradigm shift in the treatment of psoriatic arthritis, driven by the targeted action of biologics and the emergence of biosimilars. However, the consumer demand for cost-effective medicines with improved safety and efficacy profiles is likely to have a positive impact on market dynamics.

Healthcare infrastructure improvements and increased insurance coverage in emerging markets are also pivotal. Countries in Asia-Pacific and Latin America are witnessing rapid health system upgrades, enabling wider access to high-cost biologic therapies. As these markets mature, they present new opportunities for both multinational and domestic drug makers to tap into previously underserved populations.

Global Psoriatic Arthritis Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global psoriatic arthritis market report based on drug class, type, route of administration, and region:

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)
• NSAIDs
• DMARD
• Biologics
• Others
• Type Outlook (Revenue, USD Million, 2018 - 2030)
• Prescriptions
• OTC
• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)
• Topical
• Oral
• Injectable
• Regional Outlook (Revenue, USD Million, 2018 - 2026)
• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Spain
  • France
  • Italy
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Type
  • 1.2.3. Route of Administration
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Drug Class outlook
  • 2.2.2. Type outlook
  • 2.2.3. Route of Administration
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Psoriatic Arthritis Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Psoriatic Arthritis Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Psoriatic Arthritis Treatment Market: Drug Class Estimates & Trend Analysis

• 4.1. Drug Class Segment Dashboard
• 4.2. Psoriatic Arthritis Treatment Market: Drug Class Movement Analysis
• 4.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. NSAIDs
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. DMARDs
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Biologics
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Psoriatic Arthritis Treatment Market: Type Estimates & Trend Analysis

• 5.1. Type Segment Dashboard
• 5.2. Psoriatic Arthritis Treatment Market: Type Movement Analysis
• 5.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
• 5.4. Prescriptions
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. OTC
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Psoriatic Arthritis Treatment Market: Route of Administration Estimates & Trend Analysis

• 6.1. Route of Administration Segment Dashboard
• 6.2. Psoriatic Arthritis Treatment Market: Route of Administration Movement Analysis
• 6.3. Global Psoriatic Arthritis Treatment Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
• 6.4. Topical
  • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Oral
  • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Injectable
  • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Psoriatic Arthritis Treatment Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2024 & 2030
• 7.3. Continuous bioprocessing market by Region: Key Takeaways
• 7.4. North America
  • 7.4.1. U.S.
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Canada
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. Germany
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. France
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Italy
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. Spain
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.3. India
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.4. Australia
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.5. South Korea
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Argentina
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8.3. UAE
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. Key company heat map analysis, 2024
• 8.4. Company Profiles
  • 8.4.1. AbbVie Inc.
    • 8.4.1.1. Company overview
    • 8.4.1.2. Financial performance
    • 8.4.1.3. Product benchmarking
    • 8.4.1.4. Strategic initiatives
  • 8.4.2. Amgen Inc.
    • 8.4.2.1. Company overview
    • 8.4.2.2. Financial performance
    • 8.4.2.3. Product benchmarking
    • 8.4.2.4. Strategic initiatives
  • 8.4.3. Johnson & Johnson Services, Inc.
    • 8.4.3.1. Company overview
    • 8.4.3.2. Financial performance
    • 8.4.3.3. Product benchmarking
    • 8.4.3.4. Strategic initiatives
  • 8.4.4. Bristol-Myers Squibb Company
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Novartis AG
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Eli Lilly and Company
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. Pfizer, Inc.
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. UCB S.A.
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives

관련자료